Sternal Closure With SternaLock 360: First in Man Study (SL360)

January 16, 2018 updated by: Zimmer Biomet

SternaLock 360 First in Man Study: A Prospective, Randomized Controlled Trial

The SternaLock 360 Sternal Closure Device combines the techniques of rigid fixation with a cerclage material into a single sternal closure system. The cerclage material serves to facilitate sternal approximation, and the plates and screws serve to provide rigid fixation and prevent sternal movement and separation. The combination of a cerclage material in combination with plate and screw fixation may also lead to increased stability compared to either method used as a standalone means of closure.

Study Overview

Status

Completed

Conditions

Detailed Description

The purpose of this study is to evaluate a new technology for sternal closure that combines rigid plate fixation with a cerclage material in patients undergoing a cardiac surgery subsequent to a full median sternotomy. This study will evaluate intraoperative outcomes related to the surgical technique and performance of the device, sternal healing and stability, sternal wound complications and postoperative recovery (e.g. pain and functional status) in patients closed with this device. For comparative purposes, a control group of wire cerclage patients will be included.

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cape Town, South Africa
        • Groote Schuur Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

26 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients undergoing a standard midline sternotomy as a result of a cardiac surgical procedure (i.e. coronary artery bypass graft (CABG) and/or valve replacement along with other cardiac surgical procedures)
  • Patients ≥ 30 years of age
  • Patients who sign the Informed Consent

Exclusion Criteria: Pre-Operative

  • Patients with endstage renal failure who are on dialysis or post transplant patients
  • Patients taking chronic (>30 days) pre-operative narcotics
  • Patients taking chronic (>30 days) steroids, immunosuppressant (including biologic immunosuppressants such as Enbrel), or chemotherapeutics (e.g. methotrexate). Patients using a steroid inhaler for asthma should not be excluded.
  • Patients with confirmed HIV with a viral load of >10,000 copies
  • Patients with an active infection that is currently being treated
  • Patients with history or confirmed metal allergy or foreign body sensitivity
  • Patients with a previous partial or full midline sternotomy
  • Patients with previous radiation treatment of the chest
  • Patients defined within the New York Heart Association (NYHA) or Canadian Cardiovascular Society (CCS) functional Class IV for congestive heart failure: i.e., patients with cardiac disease resulting in inability to carry on any physical activity without discomfort (CCS ; NYHA)
  • Patients presenting emergent/salvage cardiac acuity as defined per the Society of Thoracic Surgeons (STS) guidelines: i.e., patients undergoing cardiopulmonary resuscitation en route to the operating room or prior to induction of anesthesia (STS)
  • Patients unwilling or unable to return for follow-up

Exclusion Criteria: Operative

  • Patients requiring delayed sternotomy closure
  • Patients with transverse sternal fractures located beneath the cerclage band on the SternaLock 360 Device.
  • Patients presenting intra-operative conditions that in the opinion of the treating surgeon would require or preclude a specific method for sternal closure, or who are not able to be closed per the protocol.
  • Use of non resorbable (beeswax) bonewax along the sternotomy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SternaLock 360
Sternal closure performed with SternaLock 360 as a primary closure system
Sternal closure with SternaLock 360
Active Comparator: Wire Cerclage
Sternal closure performed with standard wire cerclage as a primary closure system
Sternal closure with standard wire cerclage

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sternal Bone Healing
Time Frame: 6 months
Sternal bone healing score as defined by CT scan assessment at 6 months postoperatively
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sternal Pain
Time Frame: Baseline, postoperative day 3 to day 7, 1-month post-op, 3-month post-op and 6-month post-op
Pain scores obtained at pre-specified time points in 4 modalities: at rest, after using incentive spirometer, after ambulation and after forced coughing. Likert scale questionnaire.
Baseline, postoperative day 3 to day 7, 1-month post-op, 3-month post-op and 6-month post-op
Analgesic usage
Time Frame: Baseline, postoperative day 0 to day 7, 1-month post-op, 3-month post-op and 6-month post-op
Tabulation of all pain medication administered in pre-specified time points
Baseline, postoperative day 0 to day 7, 1-month post-op, 3-month post-op and 6-month post-op
Upper Extremities Functional Status
Time Frame: Baseline, 1-month post-op, 3-month post-op and 6-month post-op
Functional status of upper extremities are evaluated using 20 items that are rated on a 5-point Likert scale known as Upper Extremity Functional Index questionnaire.
Baseline, 1-month post-op, 3-month post-op and 6-month post-op
Return to Work
Time Frame: Baseline, 1-month post-op, 3-month post-op and 6-month post-op
Assessment of working status of patients before and after cardiac surgery using 7-categorical question questionnaire.
Baseline, 1-month post-op, 3-month post-op and 6-month post-op

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Brian M Hatcher, PhD, Zimmer Biomet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 4, 2015

Primary Completion (Actual)

September 5, 2017

Study Completion (Actual)

January 15, 2018

Study Registration Dates

First Submitted

February 9, 2016

First Submitted That Met QC Criteria

February 16, 2016

First Posted (Estimate)

February 19, 2016

Study Record Updates

Last Update Posted (Actual)

January 18, 2018

Last Update Submitted That Met QC Criteria

January 16, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 0614

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sternal Fracture

Clinical Trials on SternaLock 360

Subscribe